Veterinary Medicines Directorate

United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
KT15 3LS
(Reference Member State)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Detogesic 10mg/ml Solution for Injection for Horses
(Belgium, Bulgaria, Cyprus, Czech Republic, France, Germany, Greece, Ireland, Luxembourg, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, UK)

Dorum 10mg/ml Solution for Injection for Horses (Italy)

Equisedan vet 10 mg/ml Solution for Injection for Horses
(Finland, Norway, Sweden)

Equisedan 10 mg/ml Solution for Injection for Horses
(Denmark, Estonia, Latvia, Lithuania)

Equidor 10 mg/ml Solution for Injection for Horses
(Austria, Hungary)

MODULE 1

PRODUCT SUMMARY

EU Procedure number	UK/V/0226/001/DC
Name, strength and pharmaceutical form	Detogesic 10mg/ml Solution for Injection for Horses
Applicant	Vetcare Limited Kuturmaentie 2 25130 Muurla Finland
Active substance	Detomidine hydrochloride 10 mg/ml (Detomidine 8.36mg/ml)
ATC Vetcode	QN05 CM90
Target species	Horse
Indication for use	For the sedation and slight analgesia of horses, to facilitate physical examinations and treatments, such as minor surgical interventions.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies (veterinary) (HMA(v)) website (www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	21 December 2007
Date product first authorised in the Reference Member State (MRP only)	n/a
Concerned Member States for original procedure	Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC. The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy of the product was demonstrated according to the claims made in the SPC. The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The product contains the active substance detomidine hydrochloride and excipients methyl parahydroxybenzoate (E218), sodium chloride, sodium hydroxide (for pH adjustment) and water for injections.

The container/closure system comprises either a multi-dose, clear, Type 1 glass vial, with pierceable bromobutyl rubber stopper and an aluminium collar, containing 10 ml or a multi-dose, clear, cyclic olefin copolymer vial closed with a bromobutyl rubber stopper and aluminium crimp containing 15 ml. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and presence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is detomidine hydrochloride. Supporting data have been provided in the form of an Active Substance Master File (ASMF). It is considered that the manufacturing process is adequately controlled and the active substance specification has been suitably justified.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

All the other substances in the tablets comply with the requirements of the relevant European Pharmacopoeial monographs.
Certificates of conformity for the type I glass vials and the red bromobutyl rubber bungs stating compliance with the relevant monographs in the European Pharmacopoeia have been provided.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. Control on intermediate products

There are no intermediate products.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. Stability

Stability data on the active substance was discussed in the ASMF in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the finished product when stored under the approved conditions.

An in-use stability of 28 days is supported.

H. Genetically Modified Organisms

Not applicable.

J. Other Information

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years
Shelf-life after first opening the container: 28 days.

Special precautions for storage
Do not store above 25°C.
Store in the original carton in order to protect from light.
Store in a dry place.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users / the environment / consumers.

Toxicological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users / the environment / consumers.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline which showed that the following operator warnings should be included on the product literature and SPC: “Care should be taken to avoid accidental self-injection. In case of accidental self-administration, seek medical advice immediately and show the package leaflet or the label to the physician. **DO NOT DRIVE** as changes in blood pressure may be seen. Wear protective rubber gloves when using this product. Wash off splashes from the skin and eyes.”

Ecotoxicity

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

III.B Residues documentation

Residue Studies

Residue studies have been conducted in horses using either tritiated detomidine or radioimmunoassay which show that no excess of residues were reported at any injection site.

Withdrawal Periods

A withdrawal period of 2 days for meat and 12 hours for milk in horses is justified and is considered acceptable to ensure consumer safety.

IV CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies

Pharmacology

The application is made in accordance with Article 13 (1) of Directive 2001/82/EC as amended by Directive 2004/28/EC, on the basis of being a generic of a reference medicinal product, no further information is required as it has already been presented for the reference product. Bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies.

Tolerance in the Target Species of Animals

The application is made in accordance with Article 13 (1) of Directive 2001/82/EC as amended by Directive 2004/28/EC, on the basis of being a generic of a reference medicinal product, no further information is required as it has already been presented for the reference product. Bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies.

The product literature accurately reflects the type and incidence of adverse effects which might be expected.

IV.B Clinical Studies

The application is made in accordance with Article 13 (1) of Directive 2001/82/EC as amended by Directive 2004/28/EC, on the basis of being a generic of a reference medicinal product, no further information is required as it has already been presented for the reference product. Bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies.
Detogesic Solution for Injection has the same dose rate and dosing instructions, contra-indications and warnings as the reference product. It also has the same indications and warnings for use in combination with butorphanol and ketamine

which are already authorised in the UK. The applicant has submitted published references to support the use of the product with butorphanol and further published references to support the use of the product with ketamine.

The same basic claims and warnings are accepted for this product as those authorised for the reference product. The use of the product with either butorphanol or ketamine has a well-established use in the UK and some other member states, therefore the claims regarding combination use of the product are supported by the additional references.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)